Johnson & Johnson Launches PUREVUE™ 4K Ultra-HD Endoscopy Imaging System in China

Suzhou, June 9, 2020 /PRNewswire/ -- Today, Johnson & Johnson held the Mingjing (DePuy Synthes PUREVUE^TM) The delivery and launch ceremony of the Ultra-High-Definition 4K Endoscopic Imaging System (hereinafter referred to as the "Mingjing System") achieved multiple "firsts." It is in the field of arthroscopy in ChinaFirst-in-classThe 4K endoscopic imaging system is not only the first sports medicine device put into production at Johnson & Johnson’s Suzhou industrial park, but also marks the first time Johnson & Johnson has introduced the manufacturing technology for such advanced equipment to a market outside the United States. Chen Min, General Manager of the Orthopedics Division of Johnson & Johnson Medical China, along with other relevant Johnson & Johnson Medical executives in China, and Liu Hua, Member of the Party Working Committee and Deputy Director of the Administrative Committee of Suzhou Industrial Park; Zhang Xiangsheng, Deputy Director of the Suzhou Healthcare Security Administration; and Jiang Weiming, Director of the Investment Promotion Commission of Suzhou Industrial Park, among other officials from relevant departments, jointly witnessed this significant milestone of product delivery on site.

The Mingjing System embodies Johnson & Johnson’s global technological strengths and local manufacturing expertise, providing physicians with clearer visualization through real-time imaging. It enables Chinese orthopedic surgeons to treat sports injuries or degenerative bone diseases more quickly and effectively, thereby advancing the field of minimally invasive orthopedic sports surgery and benefiting patients. The successful delivery of the Mingjing System marks another significant step in Johnson & Johnson’s commitment to establishing roots and serving “Healthy China” within the Suzhou Industrial Park, following last year’s successful delivery of its first locally manufactured orthopedic spinal implants and linear cutting staplers in Suzhou. This achievement also represents a key milestone in Johnson & Johnson’s dedication to empowering innovation through its “In China, For China” strategy and supporting the upgrade of China’s high-end intelligent manufacturing sector.。

In recent years, governments at all levels in Jiangsu Province have focused on innovation to enhance the efficiency of review and approval processes through process reengineering“Jian”、Information and Data“Lian”、Service Quality and Efficiency“Excellent”, facilitating the market launch of innovative pharmaceutical and medical device products in China, while also providing strong support for the development of multinational healthcare companies, including Johnson & Johnson, in the country.

Song Weiqun, Chairman of Johnson & Johnson China, stated, “In the new normal of the post-pandemic era, the public is placing greater emphasis on sports and health, leading to a further increase in demand for high-quality healthcare solutions. The successful delivery and market launch of the Mingjing System marks the acceleration of localized, intelligent, high-end manufacturing by Johnson & Johnson Medical in China. Leveraging China’s ‘intelligent’ manufacturing capabilities empowered by our global network, we are accelerating our support for the ‘Healthy China’ initiative. The pandemic has not shaken our confidence in the long-term positive development of the Chinese market; rather, it has strengthened our resolve to implement our dual-engine strategy of ‘Development + Innovation.’ We will continue to actively support the vigorous growth of Jiangsu’s strategic healthcare industry and make new contributions to helping ‘Healthy China’ move toward a healthier future!”

Ultra HD Vision Advancing Minimally Invasive Surgery Enhancing the Supply Chain“Zhi”Manufacturing Capability

In the field of sports medicine, which focuses on the prevention, treatment, and rehabilitation of injuries to the human musculoskeletal system, arthroscopic minimally invasive surgery is an innovative surgical approach. It enables physicians to obtain comprehensive, detailed, and precise visualization of lesions, while offering the benefits of small incisions, minimal scarring, and fewer complications, thereby facilitating patient recovery. The Mingjing Ultra-High-Definition 4K Endoscopic Imaging System, used in conjunction with endoscopes and arthroscopic surgical instruments, allows physicians to directly and accurately assess, diagnose, and treat pathological conditions. The successful delivery of this system underscores Johnson & Johnson’s commitment to introducing global innovative technologies, solutions, and advanced manufacturing expertise to China, serving human health through its agile end-to-end supply chain system.

As a global leader in the healthcare industry, Johnson & Johnson is actively supporting the upgrade of high-end intelligent manufacturing capabilities in China. Johnson & Johnson currently operates nine supply chain bases in China. Among them, Johnson & Johnson (Suzhou) Medical Devices Co., Ltd., located in the Suzhou Industrial Park, is the company’s largest medical devices industrial park in China, integrating comprehensive operations including R&D, manufacturing, technological innovation and collaboration, and shared services. Recognized by the Jiangsu Provincial Department of Commerce as a “Multinational Enterprise Functional Institution,” the industrial park has made significant contributions to improving patient outcomes and advancing the healthcare industry by introducing and producing advanced orthopedic and surgical medical device products and solutions. In early 2020, Johnson & Johnson MedTech’s DePuy Synthes factory in Suzhou was honored with inclusion in the Global Lighthouse Network published by the World Economic Forum, demonstrating how advanced manufacturing can illuminate the boundless possibilities of future production through innovation.

Liu Hua, a member of the Party Working Committee and Deputy Director of the Administrative Committee of Suzhou Industrial Park, congratulated Johnson & Johnson on the successful delivery of its DePuy Synthes system. She stated, “By introducing and commencing local production in China of the first 4K endoscopic imaging system in the arthroscopy field, Johnson & Johnson will provide Chinese patients with more comprehensive solutions for joint diseases. We look forward to Johnson & Johnson bringing more high-quality projects, cutting-edge technologies, and advanced concepts to the Industrial Park in the future, working together to create a brighter future!”

Rooted in China Intensive Cultivation Upgraded Localized Layout Empowers the Future

This Year's Government Work ReportIt explicitly proposes “promoting the upgrading of the manufacturing industry and the development of emerging industries,” “advancing intelligent manufacturing,” and places significant emphasis on “continuously creating a market-oriented, law-based, and internationalized business environment.” This fully reflects the government’s commitment to attracting and retaining foreign investment, sending a strong positive signal to foreign-funded enterprises to increase their investments in China and deepen their development in the Chinese market.

Aldo Denti, Global Chairman of Johnson & Johnson MedTech Orthopaedics, sent a video message to congratulate the successful launch of this product in China: “China is one of the most important markets for Johnson & Johnson’s global business development, not only#1“...a global engine for business development, and increasingly, a global engine for innovation. The launch and delivery of the MINGJING 4K Endoscopic Imaging System in China once again underscores Johnson & Johnson’s steadfast commitment to continuing its investment in the Chinese market and serving patients better and faster. We will continue to cultivate this fertile ground for innovation, accelerating the introduction of advanced international technologies while deepening our collaboration with local partners, working hand in hand to bring about profound and meaningful change to the advancement of human health.”

From introducing, producing, and manufacturing advanced products to cultivating local innovation capabilities and building an open innovation ecosystem, Johnson & Johnson’s innovation footprint in China has grown increasingly profound. Johnson & Johnson operates nine major pharmaceutical R&D centers globally, two of which are located in China. In 2014, Johnson & Johnson established its first Innovation Center in the Asia-Pacific region in Shanghai, one of the company’s four global innovation centers. In 2019,World's Largest• The first JLABS innovation incubator in the Asia-Pacific region, established by Johnson & Johnson, has officially opened in Shanghai, providing “turnkey” services for life sciences startups. In addition, Johnson & Johnson MedTech has delivered its first batch of “Made in Suzhou” products, including orthopedic spinal implants and linear cutting staplers, from its Suzhou facility. Going forward, a series of advanced medical devices will be more agilely deployed to meet market demands, leveraging Johnson & Johnson’s continuously upgraded smart manufacturing capabilities and supply chain system in the Chinese market.

In 2019, the Johnson & Johnson Global Executive Committee announced in Beijing the launch of its China Innovation Engine, establishing the strategic position of the Chinese market with a dual-engine approach of “Growth + Innovation.” 2020 marked the 35th anniversary of Johnson & Johnson’s entry into China. Standing at this new starting point, Johnson & Johnson will continue to focus on innovation and looks forward to collaborating with more partners to support the innovation-driven development strategy for the new era, meet the health needs of patients and consumers, and contribute to the Healthy China initiative.